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Differences in the architecture, cellular and biochemical composi-
tion between normal and tumour blood vessels provide the basis
for specific vascular targeting of tumours. The newly formed
tumour vessels are usually thin-walled capillaries or sinusoids
with little more than an endothelial lining backed by a basement
membrane, and prone to spontaneous haemorrhage and throm-
bosis (Egawa et al, 1979; Bujaski et al, 1989). Tumour vessels also
seem to lack smooth muscle and innervation, are often more
permeable and tortuous, and exhibit variable diameters with
suboptimal intercapillary spacing (Warren, 1979); characteristics
which promote conditions of hypoxia and acidosis (Vaupel et al,
1989). The tumour vasculature contains vessels, particularly at the
tumour margin, that are leaky to macromolecules (Dvorak et al,
1988) which, combined with poor lymphatic drainage, can lead to
increased interstitial pressure, further impairing tumour perfusion
(Vaupel et al, 1989). Currently, not all of these differences between
tumour and normal vasculature are well understood. Nevertheless,
the fact that vascular development is an absolute requirement for
tumour growth and progression makes targeting of vasculature and
inhibition of angiogenesis very important and promising anti-
cancer strategies. Generally, in contrast to the antiproliferative
effects of anti-angiogenic therapy, anti-vascular approaches aim to
cause rapid and catastrophic shutdown in the vascular function of
the tumour, leading to extensive secondary tumour cell death.
Various approaches have been employed in anti-vascular
targeting in experimental cancer therapy. For example, manipula-
tion of tumour blood flow by agents such as hydralazine and
nicotinamide to improve the effectiveness of bioreductive agents
administered alone or in combination with radiation and/or hyper-
thermia, has been described (Chaplin et al, 1991; Bibby et al,
1993). Targeting of tumour vasculature directly, was demonstrated
using flavone acetic acid (FAA), a synthetic flavonoid, which has
been shown to cause vascular shutdown and reduction in tumour
blood flow in experimental tumours (Bibby et al, 1989a, 1991a).
These effects were found to be mediated by the production of
tumour recrosis factor a (TNF-a) (Mahadevan et al, 1990).
Unfortunately, the very promising results of FAA against experi-
mental tumours were not repeated in clinical trials. However
the FAA analogue 5,6-dimethylxanthenone-4-acetic acid
(5,6-MeXAA) (Rewcastle et al, 1989; Ching et al, 1992; Laws
et al, 1995) is currently under investigation in clinical trial.
The anti-mitotic agent colchicine was amongst the first agents
shown to possess anti-vascular activity, producing haemorrhagic
necrosis in experimental tumours (Clearkin, 1937). Tubulin is also
the site of action of the clinically used class of anticancer
compounds, the vinca alkaloids. These compounds exert their anti-
cancer effect by binding to tubulin and preventing its polymeriza-
tion to form microtubules (Chabner and Collins, 1990), thus
inhibiting a number of cellular processes, including mitosis. Taxol
also interferes with microtubule dynamics by promoting the
formation of highly stable microtubules which resist depolymer-
ization. Binding of taxol alters the conformation of the tubulin
subunit therefore greatly retarding tubulin heterodimer dissocia-
tion and promoting microtubule assembly (Schiff et al, 1979;
Schiff and Horwitz, 1980).
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Much interest has recently been generated in a series of stil-
benes isolated from the South African tree Combretum caffrum.
The most studied of these are combretastatin A-4, and its soluble
phosphate prodrug (Pettit et al, 1989, 1995) (Figure 1).
Combretastatin A-4 has been shown to bind to tubulin at the same
site as colchicine does, but with even higher affinity (McGown
and Fox, 1989; Pettit et al, 1989). Its prodrug, combretastatin A-4
disodium phosphate, has been shown to induce vascular shutdown
in subcutaneous (s.c.) experimental tumours at doses less than
one-tenth of the maximum tolerated dose (MTD) and to be more
cytotoxic to rapidly proliferating rather than quiescent endothelial
cells in vitro (Dark et al, 1997).
In this study initial experiments using a refractory s.c. murine
adenocarcinoma (MAC 15A s.c.) were performed in order to
confirm the previously reported effects of combretastatin A-4 and
its prodrug on tumour growth delay at well-tolerated doses and to
assess vascular damage in these tumours. Subsequent work
concentrated on orthotopic murine (MAC 15) and human
(SW620) colon adenocarcinomas, since the orthotopic site is
thought by many to be more clinically relevant. In the MAC 15
orthotopic model, tumour growth in the colon is often accompa-
nied by formation of metastasis in other parts of the body (Cowen
et al, 1995). Therefore, the anti-tumour effects of combretastatin
A-4 and its prodrug were assessed in the primary site and, where
appropriate, in metastatic deposits. A mechanistic study to
examine the ability of these compounds to directly interfere with
human umbilical vein endothelial cells (HUVEC) and alter their




NMRI mice (B&K Universal Ltd, Hull, UK) and nude-NCR-Nu
mice (NCI, Frederick, MD, USA), aged 6–8 weeks were used.
Mice received CRM diet (Special Diet Services, Witham, UK) and
water ad libitum. All animal procedures were carried out under a
project licence issued by the Home Office, London, UK and were
performed according to UK guidelines (UKCCCR Guidelines,
1998).
Subcutaneous tumours
MAC 15 is a moderately rapidly growing, well-differentiated,
tubular adenocarcinoma originally induced in the colon of NMRI
mice (Double et al, 1975). MAC 15A tumours are poorly differen-
tiated with relatively fast growth rate and were produced by s.c.
injection of MAC 15A cells from ascitic fluid. MAC 15A ascites
tumour was derived by intraperitoneal (i.p.) implantation of MAC
15 tumour pieces, using the method described by Double and
Cifuentes de Castro (1978). Human colon SW620 s.c. tumours
were obtained from s.c. injections of the corresponding tumour
cell line and passaged routinely in NCR-Nude mice.
Orthotopic transplantation procedure
This was performed as previously described by Cowen et al
(1995). The MAC 15 s.c. donor tumour was aseptically removed
from the s.c. site, placed in a Petri dish containing sterile saline,
penicillin and streptomycin (Sigma, Poole, UK), and the viable
tissue was cut into 1-mm3 pieces. The NMRI mice used had their
abdomen shaved and were anaesthetized with Metophane inhala-
tion anaesthetic (C-Vet, Leyland, UK). An incision was made on
the lower left of the midline and the caecum was gently external-
ized. The piece of tumour was then placed on the surface of the
caecum and covered with a small disc of cellulose acetate
membrane (type RA- pore size 1–2 mm, Millipore UK Ltd,
Watford, UK). The implant was fixed into position with Histoacryl
blue tissue adhesive (Davis & Gek, Cyanamid, UK). The caecum
was then returned to its normal position in the abdomen and the
incision in the abdominal wall sealed using the tissue adhesive.
Finally the skin was closed using autoclips, which were removed
once sufficient wound healing had occurred. Orthotopic tumours
usually developed 6–8 weeks after the transplantation. Identical
procedures were carried out with SW620 human tumours in NCR
mice.
Compounds
Combretastatin A-4 (MW: 316) was dissolved in 10% dimethyl-
sulphoxide (DMSO)/oil and combretastatin A-4 disodium phos-
phate (MW: 440) in saline. Both agents were administered i.p. in
mice at 0.1 ml per 10 g of body weight.
Assessment of tumour growth
Tumour volumes were assessed by caliper measurements of the
perpendicular diameters and the volumes estimated using the
equation: Volume = (a2 ´ b)/2 (Geran et al, 1972), where a is the
smaller and b is the larger diameter of the two.
Histological assessment
Tumours were collected and fixed in Bouin’s fixative for 24 h.
These were then dehydrated and embedded in paraffin. Sections
were cut at 5-mm and stained using haematoxylin and eosin
(H&E). A minimum of five sections from each tumour was exam-
ined. As the prodrug, rather than the lead compound, was selected
for clinical evaluation the extent of necrosis in tumours from
prodrug treated animals was quantifed and the percentage necrosis
determined by image analysis (Seescan, Cambridge, UK) using
the method described by Laws et al (1995).
Hoechst-33342 studies
H-33342 (bisBenzimide, Sigma) was dissolved in sterile saline
and administered at 40 mg kg–1 intravenously (i.v.) (volume
5 ml kg–1) (Smith et al, 1988). One minute after injection the















Figure 1 The chemical structures of (A) combretastatin A-4 and
(B) combretastatin A-4-disodium phosphate1320 K Grosios et al
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resected. Tumours were wrapped in aluminium foil and immedi-
ately immersed in liquid nitrogen for subsequent frozen
sectioning. Frozen sections (5-mm) were cut on a cryostat (Bright
Instrument Co. Ltd, Huntingdon, UK) and viewed at ´25 objective
magnification on a light microscope using incident UV illumina-
tion. Perfusion was observed as fluorescence and counts were
performed, where squares containing fluorescence, in a graticule
with a grid of 400 squares, were counted as positive. A minimum
of five sections per tissue was examined and five fields counted
per section.
Statistical analysis of data
All the numerical data obtained from chemotherapy experiments,
cytotoxicity assays, necrosis analysis or fluorescent dye staining
are given as the mean values ± standard deviation (s.d). Statistical
analysis of chemotherapy and image analysis results was carried
out using the Mann–Whitney U-test or Student’s t-test.
HUVEC culture
All cell culture media and reagents were purchased from Sigma.
HUVEC were isolated according to the method described by Jaffe
et al (1973). Umbilical cords (~20 cm) from elective Caesarean
sections were received from the Maternity Unit of Bradford Royal
Infirmary. Isolated HUVEC were grown in medium M199 supple-
mented with 10% human serum and 100 mM sodium pyruvate,
200 mML -glutamine, 5000 IU ml–1 penicillin and 5000 mg ml–1
streptomycin. All culture flasks used had been previously coated
with 0.2% gelatin in phosphate-buffered saline (PBS).
HUVEC network formation assay
Type I calf-skin collagen solution (900 ml of 1.1 mg ml–1 in 0.01 N
acetic acid) was mixed with 100 ml of 103 (ten times concen-
trated) MEM and 150 ml of freshly prepared 7.5% (w/v) sodium
bicarbonate solution. This collagen solution (300 ml) was then
added to each well, in 24-well plates and incubated at 37°C until
the gels set (approximately 15–20 min). Pre-warmed culture
medium was then added to wells and the gels incubated for 3 h to
equilibrate. After the 3-h incubation period the medium was
removed and replaced with 0.5 ml of fresh pre-warmed medium,
containing 1 ´ 105 cells ml–1 and the gels were incubated for a
further 24 h (37°C, 5% carbon dioxide). The medium was then
carefully removed and a second layer of collagen, of the same
composition as the first one, was added and left to set before
addition of fresh pre-warmed medium. The following day HUVEC
networks could be observed.
HUVEC migration assay
The ability of HUVEC to migrate through collagen was examined
using Transwell chambers (Costar, High Wycombe, UK). The
membrane of the upper chamber of transwells was coated with
100 ml of the same collagen solution as that used in the tube forma-
tion assays was left at 37°C for approximately 20 min to gel.
Before being used gels were incubated in medium for 3 h. Cells
(5 ´ 103) were then seeded on the gel and left at 37°C for 2 h
before the media in the wells were replaced with either fresh
medium or medium containing non-cytotoxic concentration of the
test compound (combretastatin A-4 or A-4 phosphate). Following
24-h incubation at 37°C, the transwell was removed and fixed for
2 h in Bouin’s solution. The filters were then removed, stained
with H&E and microscopically examined for the presence of
HUVEC. Each exposure was performed at least in triplicate.
HUVEC neutral red assay
The neutral red (NR) assay was performed as described by
Borenfreund et al (1990). Gelatinized, flat-bottom, 96-well plates
(Costar) were seeded with 4 ´ 103 cells per well and incubated for
18 h at 37°C. The cells were then incubated with drug in culture
medium or DMSO at 37°C, 5% carbon dioxide, for the appropriate
time. After this the cells were washed with Hank’s balanced saline
solution (HBSS) and the medium was replaced with medium
containing NR dye (40 mg ml–1), incubated for 3 h following which
the cells were fixed by adding 100 ml of 0.5% formalin–calcium
chloride to each well. The dye was extracted by adding 200 ml of
1% acetic acid/50% ethanol per well and the absorbance deter-
mined at 540 nm using an enzyme-linked immunosorbent assay
(ELISA) spectrophotometer (Multiscan Plus, Labsystems, Life
Sciences International Ltd, Basingstoke, UK). Each experiment
was performed at least in triplicate. A calibration curve which
illustrated linearity between cell number and absorbance at
540 nm was also performed.
A
C
Figure 2 Representative sections showing the morphological appearance
(H&E staining) of MAC 15A s.c. tumours in NMRI mice treated with single i.p.
dose combretastatin A-4 (150 mg kg–1), (A) control, (B) 2 h, (C) 4 h, (D) 24 h.
V: viable tumour area, arrow: area of necrosis (Bar: 30 mm)Activity of combretastatin A-4 and its prodrug 1321
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F-actin staining
Staining of cytoskeletal F-actin was achieved using rhodamine
conjugated phalloidin. HUVEC were grown on thermanox cover-
slips (ICN Biomedicals Inc, Oxton, UK). Following treatment
with the test compound the coverslips were washed with PBS,
permeabilized in 0.5% Triton X-100 in PBS, fixed in 1.5%
formaldehyde and washed in PBS. Coverslips were incubated for
1 h in the rhodamine–phalloidin solution (1 mg ml–1), rinsed in
PBS and mounted using 80% glycerol in PBS. The coverslips
were then microscopically examined under fluorescence.
Untreated controls were also processed in the same way.
Tubulin staining
Tubulin staining was performed using a three-step indirect
immunoperoxidase technique. HUVEC were grown on thermanox
coverslips and, following treatment with the test compound, were
washed in PBS, permeabilized in 0.5% Triton X-100 in PBS and
fixed in 1.5% formaldehyde in PBS for 1 h. After washing in PBS
the coverslips were incubated in a humid chamber with the
primary antibody (mouse monoclonal anti-b tubulin antibody,
1:400 dilution, Amersham International plc, Little Chalfont, UK)
for 2 h. Following this, the coverslips were washed in PBS and
incubated with the secondary antibody (rabbit anti-mouse biotinyl-
ated, Dako, High Wycombe, UK) for 45 min. The coverslips
were then washed again in PBS and incubated with avidin–
biotin–peroxidase complex (Dako) for 30 min. Visualization was
carried out using the chromagen 3,3¢-diaminobenzidine
tetrahydrochloride (Sigma) and enhancement was with copper
sulphate solution for 5 min. Coverslips were finally counterstained
with haematoxylin, dehydrated and mounted with DPX. Control
coverslips were processed by the same procedure.
RESULTS
In vivo studies
The effects of combretastatin A-4 on MAC 15A s.c. tumour
growth
The ability of combretastatin A-4 to cause tumour growth delay
was assessed in MAC 15A s.c. tumours. Treatment began when
tumours could be reliably measured by calipers, i.e. when tumours
had reached minimum diameters of 4 ´ 5 mm. Initial treatment of
mice bearing such tumours with single i.p doses of combretastatin
A-4 (100 mg kg–1) resulted in a modest tumour growth delay of
1.7 days (P < 0.05) (Table 1). Treatment with 50 mg kg–1 did not
induce a growth delay. Subsequent experiments with a higher dose
of combretastatin A-4 (200 mg kg–1) in the same tumour model did
not further increase tumour growth delay but did cause toxicity
with three out of five mice having to be killed. Two mice were
killed, one on day 2 and the other on day 3. Further studies with
the water-soluble prodrug (100 mg kg–1) produced similar anti-
tumour effects (Table 1). A further experiment in which mice were
treated with the same dose of the prodrug on day 1 after tumour
cell inoculation (prior to vascularization) resulted in no measur-
able tumour growth delay.
Morphological studies in 15A s.c. models
The effects of combretastatin A-4 and its prodrug, combretastatin
A-4 disodium phosphate, on tumour morphology were assessed in
NMRI mice bearing MAC 15A s.c. tumours. Four mice were
treated with 150 mg kg–1, single i.p dose (the dose that was found
to cause tumour growth delay with no obvious toxicity) of
combretastatin A-4. A control group of four mice was injected
with the solvent. Animals were killed 24 h after treatment, their
tumours removed, fixed, processed and stained and a number of
sections from each tumour was examined. All MAC 15A s.c.
tumours from untreated animals showed their usual histological
appearance of poor differentiation and limited necrosis (Figure
2A). In contrast, all the tumours from treated mice showed very
extensive areas of haemorrhagic necrosis. Some small areas of
viable tumour could also be found, particularly in the tumour
periphery. The time taken for the haemorrhagic necrosis to occur
was also investigated. A number of sections from MAC 15A s.c.
tumours excised from groups of four treated and four control
NMRI mice were examined at 1, 2 and 4 h after treatment.
Following a single i.p dose of 150 mg kg–1 combretastatin A-4 or
100 mg kg–1 of the prodrug, the first signs of haemorrhagic
necrosis appeared 2 h after the injection. No necrosis was seen at
1 h but tumours appeared extensively necrotic 4 h after the
Table 1 The ability of combretastatin A-4* or the prodrug** to produce a
growth delay was examined in NMRI mice bearing subcutaneous MAC 15A
murine colon adenocarcinoma
Dose Mean time Median time Growth Significance
(mg kg–1) to RTV2 (±s.d.) to RTV2 delay
(days) (days) (days)
50* 1.45 (± 0.66) 1.52 None NS
100* 2.96 (± 0.70) 3.20 1.70 P < 0.05
200* Toxic
Control 1.89 (± 0.30) 1.50
100** 3.83 (± 1.19) 3.83 1.53 P < 0.05
Control 2.40 (± 0.77) 2.30
Treatment began when tumours had reached a minimum size of 4 ´ 5m m
and effect of therapy was monitored by daily caliper measurements of the
tumour (n ³ 6). Semi-log plots of relative tumour volume against time were
made and time taken for tumour-doubling to occur was recorded.
Significance of growth delay was determined by a Mann–Whitney U-test
comparing doubling time in control versus treated tumours.
Table 2 Percentage area of necrosis in sc MAC 15A tumours 24 h after
treatment with combretastatin-A4 prodrug as determined by image analysis
Treatment Area of necrosis (mean % ± s.d.)
100 mg kg–1 91.74 ± 10.51
Control 10.53 ± 16.95
P < 0.001.
Table 3 Percentage area of necrosis in orthotopically transplanted MAC 15
tumours 24 h after treatment with combretastatin-A4 prodrug as determined
by image analysis
Treatment Area of necrosis (mean % ± s.d.)
100 mg kg–1 97.34 ± 9.99
Control 4.21 ± 6.74
P < 0.001.1322 K Grosios et al
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injection (Figure 2 B,C) The massive necrosis resulting 24 h after
treatment with combretastatin A-4 is demonstrated in Figure 2D.
In order to quantify the extent of necrosis produced by the
prodrug, sections from the tumours removed 24 h after treatment
underwent image analysis. This analysis demonstrated massive
necrosis in treated tumours (Table 2). Similar morphological
changes were seen following treatment of NCR-Nu (immunocom-
promised) mice bearing MAC 15A s.c. tumours with 150 mg kg–1
combretastatin A-4 and 100 mg kg–1 combretastatin A-4
phosphate.
Orthotopic model studies
The antitumour effects of combretastatin A-4 and its phosphate
derivative were also assessed in the MAC 15 orthotopic tumour
model. After MAC 15 orthotopic transplantation, the ‘primary’
adenocarcinoma development was often followed by development
of tumour metastatic deposits in the lung, lymph nodes, liver and
other sites. Unfortunately, assessment of the development of
metastasis is possible only after the animal has been killed. Five
NMRI mice bearing MAC 15 orthotopic tumours were treated
with a single i.p. dose of 150 mg kg–1 and another three NMRI
mice bearing MAC 15 orthotopic tumours were treated with a
single i.p. dose of 100 mg kg–1 combretastatin A-4 disodium phos-
phate. These doses having been previously demonstrated to cause
haemorrhagic necrosis in the s.c. model. Twenty-four hours after
treatment the tumours were removed and microscopic examination
of a number of sections from each tumour showed that extensive
haemorrhagic necrosis was present in the ‘primary’, orthotopic
tumour. As can be seen in Figure 3, the normal colon appears
unaffected. Again, however, areas of viable tumour could also be
seen in the tumour periphery. Tumours from control animals and
those treated with the prodrug were analysed for extent of necrosis.
As can be seen from Table 3 the effects of the prodrug are very
marked. Orthotopic tumours removed from two animals treated
with 75 mg kg–1 combretastatin A-4 phosphate were very similar
in appearance with extensive haemorrhagic necrosis.
In addition to the MAC 15 orthotopic tumours, two NCR-Nu
mice bearing SW 620 orthotopic human colon tumours were
treated with 100 mg kg–1, single i.p. dose of combretastatin A-4
phosphate. The same effects as those seen in the treated MAC 15
orthotopic tumours (Figure 3) were also observed in all the
sections examined from these tumours. Although insufficient
samples were available for absolute quantification, in this case
very extensive haemorrhagic necrosis was seen in treated but not
control mice. Again a rim of viable tumour was observed in the
periphery.
One important characteristic of the MAC 15 orthotopic tumour
model is that the primary tumour as well as some of the metastatic
deposits (including body wall, axillary lymph node and kidney
deposits) (Figure 4) develop extensive vasculature. In contrast,
deposits that form in the lungs of the animal remain relatively
small in size and avascular (Figure 5).
The profound effects of these compounds on the primary
A C
D B
Figure 3 Representatative sections showing the morphological appearance (H&E staining) of panel I (left) MAC 15, and panel II (right) SW 620, orthotopic
tumour in mice (A and C) twenty-four hours after treatment with single i.p. dose of combretastatin A-4 (150 mg kg–1) for MAC 15 or combretastatin A-4
phosphate (100 mg kg–1) for SW620. (B and D) tumours from control animals. Arrow: viable tumour, N: necrosis, C: normal colon (Bar: 30 mm)Activity of combretastatin A-4 and its prodrug 1323
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tumours were also accompanied by effects on metastatic tumour
deposits. Liver deposits were not found in any of the mice treated,
but tumour deposits were excised from the abdominal wall (in
three animals), kidney (in one animal) and lymph nodes (in two
animals) of treated mice. Microscopic examination of a number of
sections from all of these deposits showed that they all exhibited
large areas of necrosis (Figure 6A, kidney).
Three of the mice treated with combretastatin A-4 and three of
the mice treated with combretastatin A-4 disodium phosphate had
developed avascular tumour metastatic deposits in their lungs.
These remained unaffected by the treatment, i.e. no signs of
necrosis were seen in any of the deposits (Figure 6B).
Vascular shutdown studies
Vascular shutdown studies using Hoechst 33342 fluorescent dye
showed that treatment with a single i.p. dose of 100 mg kg–1
of combretastatin A-4 disodium phosphate resulted in almost
complete vascular shutdown in both MAC 15A s.c. and MAC 15
orthotopic tumours, 4 h after treatment The same results were also
obtained in MAC 15A s.c. tumours, 4 h after treatment with a
single i.p. dose of 150 mg kg–1 of combretastatin A-4 (in all three
cases four tumour-bearing mice were treated and another four
were used as controls). The vascular counts for untreated MAC
15A s.c. and MAC 15 orthotopic tumours were 47.56 (s.d. 7.94)
and 69.97 (s.d. 16.43) respectively, whereas in all treated tumours
very limited fluorescence could be seen, again only in the tumour
periphery.
In vitro studies
Initial experiments were performed using the NR assay in order to
establish non-cytotoxic concentrations of these compounds.
Employing 24-h exposure to 0.31 mM and 0.40 mM of combreta-
statin A-4 and combretastatin A-4 disodium phosphate respec-
tively resulted in less than 40% of HUVEC cell death, i.e. 68.3%
(s.d. 6.87) HUVEC viability after exposure to combretastatin A-4
and 63.1% (s.d. 2.82) cell viability after exposure to combretas-
tatin A-4-phosphate. At the same concentrations and exposure
time the percentage cell survival in a 6-day assay was approxi-
mately 80% (85.9%, s.d. 8.90 for combretastatin A-4, and 83.5 s.d.
5.62 for A-4 phosphate).
Figure 4 (A) Immunostaining of frozen section of MAC 15 tumour using an
antibody to CD31, showing blood vessel development in the tumour in the
orthotopic site in NMRI mouse. (B) Immunostaining of frozen section of body
wall deposit developing following MAC 15 orthotopic transplantation in NMRI
mouse. V: blood vessel, T: tumour, M: muscle (Bar: 30 mm)
Figure 5 Frozen section of tumour deposit formed in the lung of NMRI mouse following MAC 15 orthotopic transplantation showing the absence of blood
vessel development. (A) Immunostaining using an antibody to von Willebrand factor and (B) Hoechst 33342 fluorescent dye staining. T: tumour deposit,
Lu: lung, (Bar: 30 mm)1324 K Grosios et al
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Effects on HUVEC networks in collagen
Addition of media containing either 0.31 mM of combretastatin
A-4 or 0.40 mM combretastatin A-4 disodium phosphate (non-
cytotoxic concentrations) to already established endothelial cell
networks in type I calf-skin collagen resulted in rapid disruption of
these networks (Figure 7). Disruption started after approximately
4 h and was complete after 24 h of exposure to the compounds.
These exposures were performed at least in triplicate and the same
degree and time of appearance of network disruption was seen in
all the exposed wells. In addition, the same non-cytotoxic concen-
trations of either 0.31 mM of combretastatin A-4 or 0.40 mM
combretastatin A-4 disodium phosphate inhibited migration of
HUVEC through type I calf-skin collagen in transwell chambers
(results not shown).
Effects on HUVEC cytoskeleton
Treatment of HUVEC with non-cytotoxic doses of combretastatin
A-4 or combretastatin A-4 disodium phosphate (0.31 mM and
0.40 mM respectively) resulted in complete cytoskeletal disorgani-
zation and disruption of both F-actin filaments and tubulin micro-
tubules (Figure 7). This disruption was seen approximately 1 h
after treatment and was uniform across the cell monolayer on the
coverslip.
DISCUSSION
The main aim of this study was to investigate the role of vascula-
ture in the anti-tumour response of a novel compound, combretas-
tatin A-4 and its water-soluble disodium phosphate derivative, and
to provide further insights into their mechanism of action. This
study, has demonstrated major effects of combretastatin A-4 and
its prodrug in human and murine tumours in clinically relevant
sites. Experiments with both the parent compound and its prodrug
had previously shown that they caused an increase in vascular
resistance by a factor of at least 3 in rat P22 tumour perfused
ex vivo. In addition, treatment with the prodrug resulted in
haemorrhagic necrosis in CaNT and MDA-MB-231 tumours
(Dark et al, 1997). We also found that treatment of MAC 15A s.c.
tumours with combretastatin A-4 and its water-soluble prodrug
caused tumour growth delay, which was accompanied by vascular
shutdown 4 h after treatment. In addition, extensive haemorrhagic
necrosis was seen with both combretastatin A-4 and A-4 phos-
phate, the appearance of which started 2 h after treatment and by
24 h was very extensive.
Extensive haemorrhagic necrosis was also observed in ortho-
topic MAC 15 tumours and the orthotopic human colon tumour
xenograft SW620 at 24 h (the time point examined). Hoechst
33342 studies in the treated MAC 15 orthotopic tumours showed
the presence of almost complete vascular shutdown 4 h after treat-
ment. At these dose levels neither the parent compound nor its
prodrug affected the normal colon, indicating possible tumour
specificity. In the treatment of any disease, compounds are
required that can achieve their effects at doses much lower than
the MTD. Extensive necrosis was observed in orthotopic MAC 15
tumours treated with 100 mg kg–1 and also doses down to
75 mg kg–1 of combretastatin A-4 disodium phosphate. Dark et al
(1997) described similar effects in s.c. tumours treated with doses
of combretastatin A-4 disodium phosphate that were less than 10%
of the MTD. This could prove an important aspect in the clinical
evaluation of combretastatin A-4 prodrug as anti-vascular effects
may occur well below the MTD in humans. Taxol exerts its effects
at doses close to MTD (Rowinsky et al, 1990) and the same is true
for other compounds known to interfere with vasculature, such as
colchicine, vinblastine (which also binds tubulin), FAA and
5,6-MeXAA (Bibby et al, 1989a; Baguley et al, 1991). The studies
described indicate that use of combretastatin A-4 may exert a
more selective action against tumour vasculature than other
anti-microtubule agents.
The fact that immune status can influence response to anti-
tumour agents has been shown with FAA (Bibby et al, 1991b).
However, treatment of MAC 15A s.c. tumours in NCR-Nu mice
with combretastatin A-4 or its phosphate prodrug exhibited the
same marked necrosis to that observed in NMRI mice (data not
A B
Figure 6 Morphological appearance (H&E staining) of metastatic tumour deposits in (A) kidney, (B) lung, of NMRI mice bearing MAC 15 orthotopic tumours
and treated with single, i.p. dose combretastatin A-4 (150 mg kg–1). Arrow: necrotic area, T: viable tumour, Lu: lung (Bar: 30 mm)Activity of combretastatin A-4 and its prodrug 1325
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shown) as did SW620 tumours indicating that this is unlikely to be
a contributory factor for these compounds.
The anti-vascular effects of agents such as FAA have been
attributed in part to their ability to induce TNF-a release
(Mahadevan et al, 1990), whereas anti-vascular effects seen with
some tubulin-binding agents do not involve TNF-a (Hill et al,
1995). Dark et al (1997) also reported, but no data were presented,
that these effects of combretastatin A-4-phosphate do not involve
TNF-a. Work in our laboratory failed to detect TNF-a in the
serum of mice bearing tumours responding to combretastatin A-4.
Since tumour metastasis is a major problem in cancer therapy,
compounds that are able to specifically affect the viability of
metastases would prove very useful. The necrosis in metastatic
deposits caused by combretastatin A-4 and its prodrug in this
study at well-tolerated doses suggests that the water-soluble
prodrug might be clinically useful. To date, the observation that
haemorrhagic necrosis occurs only in vascularized tumour
deposits is the clearest evidence that a direct effect of these
compounds on tumour vasculature is essential for anti-tumour
activity in vivo. It might be assumed that avascular deposits are
unlikely to receive such high concentrations of drug as those with







Figure 7 Panel I (top): appearance of HUVEC networks in type I calf skin collagen, 4 h after treatment. (A) Control (incubated with media containing 1%
DMSO), (B) treated with combretastatin A-4 (0.31 mM), (Bar: 60 mm). Panel II (middle): appearance of HUVEC cytoskeleton showing F-actin, (C) untreated,
(D) 1 h after treatment with 0.31 mM combretastatin A-4 (Bar: 15 mm). Panel III (bottom): appearance of HUVEC cytoskeleton, showing b-tubulin, (E) untreated,
(F) 1 h after treatment with 0.31 mM combretastatin A-4 (Bar: 15 mm)1326 K Grosios et al
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effects, but previous data have shown avascular MAC15A lung
metastases to be equally as sensitive to 5-fluorouracil, chloram-
bucil and tauromustine as well-vascularized s.c. MAC15A
tumours (Bibby et al, 1989b).
The ideal anti-vascular agent might have the ability to exert
potent effects on both tumour cells as well as endothelial cells,
e.g. vinblastine (Hill et al, 1995). Preferably it should exert its
immediate effects on dividing endothelial cells, the cell type that it
comes into direct contact with from the blood. The use of HUVEC
cultures provided further insights into the mechanism of action of
these two combretastatins and their ability to influence endothelial
cell behaviour. Endothelial cells, including HUVEC, form cell
networks when grown on specific substrata such as fibronectin,
matrigel and type I collagen (Schor et al, 1983). This ability
depends on cell density and electron microscopy studies have
shown that the tubular networks that are formed consist of cells,
held together by junctional complexes. They display a well-
oriented cell polarity and form a lumen (Maciag et al, 1982;
Montesano et al, 1983).
In this study, non-cytotoxic concentrations of combretastatin A-
4 and the disodium phosphate derivative caused relatively rapid
disruption of HUVEC networks and inhibited HUVEC migration
through type I collagen. This implies that the anti-tumour effect
may be brought about by the direct action of these agents on
endothelial cells. Although it is likely that this is a feature of
tubulin-binding drugs, in general these effects are seen with
combretastatin-A4 at concentrations that are well below those that
are cytoxic to endothelial cells and other cell types (Dark et al,
1997). F-actin and b-tubulin staining studies indicated that these
effects result from the ability of combretastatin A-4 to bind to
tubulin and cause complete cytoskeletal disorganization in
endothelial cells. If this happened in vivo it may lead to collapse of
the tumour vasculature. Both actin and tubulin appeared distorted
in HUVEC after approximately 1 h of exposure which correlates
with and may explain the timing of the appearance of haemor-
rhagic necrosis and vascular shutdown in vivo. Since combreta-
statin A-4 binds to tubulin, it is likely that tubulin disorganization
is immediately followed by actin disorganization. These two
cytoskeletal components are in very close association and appar-
ently once one of them is disturbed the other one will not remain
unaffected and would not be able to maintain cellular architecture
(Birchmeier, 1984). Vero cells (African Green monkey kidney
cells) have exhibited the same tubulin disorganization following
treatment with combretastatin, and treatment of HUVEC with a
similar compound, combretastatin A-1 resulted in the same tubulin
disorganization as A-4 (Woods et al, 1995).
In conclusion, combretastatin A-4 and its disodium phosphate
prodrug cause vascular shutdown and haemorrhagic necrosis in
vascularized but not in avascular tumours in mice. These effects
were observed not only in MAC 15A s.c. tumours and orthotopic
MAC 15 and SW620 tumours in a clinically relevant site, but also in
metastases. The in vitro studies indicate that these compounds do
have the ability to interfere with endothelial cell behaviour and this
might be the way they exert their actions. It is important that the
clinical evaluation of combretastatin A-4-disodium phosphate be
accompanied by appropriate investigation of anti-vascular effects.
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